Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.0052W HIGH $11.22
Volume
5.12 M
Value Traded
38.91 M
Short % Float
15.87%
+1.47%Week
-5.85%1 Month
-20.67%3 Month
-13.28%6 Month
-41.21%5 Year
+32.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.12 B
EPS (TTM)
-1.51
P/E Ratio
-
Ent. Value
2.16 B
Total Shares
255.54 M
Float Shares
219.66 M
Insiders
14.04%
Institutions
90.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BCRX Catalyst Timeline
Dated clinical, regulatory and corporate events for BioCryst Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioCryst Pharmaceuticals, Inc.
897Total events
7Upcoming
214Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
BioCryst forms Scientific Advisory Board of seven scientific and industry leaders
▲FDA ApprovalORLADEYOApprovedFDA Decision
MHLW grants marketing approval for ORLADEYO in pediatric HAE patients aged 2 to <12 years in Japan
hereditary angioedema (HAE)source ↗
◆Poster PresentationnavenibartPresentation
Clinical Outcomes with Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
hereditary angioedemasource ↗
◆Poster PresentationORLADEYOApprovedPresentation
Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
hereditary angioedemasource ↗
◆Poster PresentationORLADEYOApprovedPresentation
Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
hereditary angioedemasource ↗
◆Poster PresentationORLADEYOApprovedPresentation
Real-World Patient Characterization, Prior Long-Term Prophylactic Prescribing Patterns, and Treatment Outcomes for Adults on Berotralstat with Hereditary Angioedema in Japan
hereditary angioedemasource ↗
▲Poster PresentationnavenibartPresentation
Post hoc analysis of ALPHA-STAR study evaluating clinical outcomes across patient subgroups
hereditary angioedemasource ↗
▲Enrollment CompletenavenibartTrial
Enrollment completion in ALPHA-ORBIT pivotal study of navenibart
hereditary angioedemasource ↗
◆Poster PresentationPresentation
Poster EE69: Healthcare Resource Utilization in Pediatric HAE Patients
hereditary angioedema (HAE)source ↗
▲First Patient DosedBCX17725Trial
Dosing began in Part 4 of Phase 1 trial of BCX17725
Netherton syndromesource ↗
▲Partnership / LicensenavenibartCorporate
European licensing agreement with Neopharmed Gentili for navenibart
hereditary angioedemasource ↗
▲Partnership / LicensenavenibartCorporate
Licensing agreement with Neopharmed Gentili for European commercial rights to navenibart
hereditary angioedemasource ↗
◆Management ChangeCorporate
Appointment of Sandeep M. Menon as Chief Research and Development Officer
●Management ChangeCorporate
Appointed Sandeep M. Menon as Chief Research and Development Officer
◆Oral PresentationPresentation
BioCryst to present at T.D. Cowen 46th Annual Health Care Conference
◆Oral PresentationnavenibartPresentation
Late-breaking presentation highlighting positive interim results of long-term, open-label ALPHA-SOLAR trial for navenibart at AAAAI 2026
hereditary angioedema (HAE)source ↗
◆Oral PresentationORLADEYOApprovedPresentation
Presentation of six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO at AAAAI 2026
hereditary angioedema (HAE)source ↗
◆Poster PresentationORLADEYOApprovedPresentation
Poster presentations of ORLADEYO data at AAAAI 2026
hereditary angioedema (HAE)source ↗
◆Poster PresentationnavenibartPresentation
Poster presentations of navenibart data at AAAAI 2026
hereditary angioedema (HAE)source ↗
◆Quarterly UpdateCorporate
BioCryst to report Q4 2025 financial results and host conference call
▲FDA ApprovalORLADEYOApprovedFDA Decision
FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years
hereditary angioedema (HAE) in patients aged 2 to <12 yearssource ↗
▲AcquisitionCorporate
BioCryst completes acquisition of Astria Therapeutics
hereditary angioedemasource ↗
▲Partnership / LicensenavenibartCorporate
Acquisition adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3
hereditary angioedemasource ↗
●Debt Royalty FinancingCorporate
BioCryst drew ~$396.6 million from Blackstone financing facility
▼Program DiscontinuationavoralstatDiscontinuedCorporate
Ended development of avoralstat for diabetic macular edema
diabetic macular edemasource ↗
◆PDUFA DateORLADEYOApprovedRegulatory Filing
PDUFA target action date for ORLADEYO oral granule NDA for pediatric HAE prophylaxis
hereditary angioedema (HAE) in pediatric patients aged 2 to <12 yearssource ↗
▲FDA ApprovalORLADEYOApprovedFDA Decision
FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years
hereditary angioedema (HAE) aged 2 to <12 yearssource ↗
●EU MAA SubmissionORLADEYOApprovedEx-US Regulatory
EMA application filed for ORLADEYO oral pellets in pediatric HAE
hereditary angioedema (HAE) aged 2 to <12 yearssource ↗
●PMDA MilestoneORLADEYOApprovedEx-US Regulatory
PMDA application filed for ORLADEYO oral pellets in pediatric HAE
hereditary angioedema (HAE) aged 2 to <12 yearssource ↗
▲AcquisitionCorporate
Early termination of HSR waiting period for acquisition of Astria Therapeutics
▲Quarterly UpdateCorporate
Company expects to approach positive EPS and positive cash flow in 2H 2025
◆Poster PresentationORLADEYOApprovedPresentation
Poster #R117: Emergency Department Experiences of Young Patients with Hereditary Angioedema and Their Caregivers
hereditary angioedema (HAE)source ↗
◆Poster PresentationORLADEYOApprovedPresentation
Poster #R109: Burden of Attack for Young Patients with Hereditary Angioedema and Their Caregivers
hereditary angioedema (HAE)source ↗
◆Poster PresentationORLADEYOApprovedPresentation
Poster #R089: Hereditary Angioedema Attack Rates in Children 2-12 with Oral Prophylactic Berotralstat Over One Year
hereditary angioedema (HAE)source ↗
◆Poster PresentationORLADEYOApprovedPresentation
Second interim analysis of APeX-P trial in pediatric HAE patients aged 2 to <12 years
hereditary angioedema (HAE)source ↗
Past FDA Catalysts and PDUFA Decisions
How BCRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | BCX17725 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$406M
Pipeline Value
$3.9B
Commercial Value
Undervalued
Valuation Signal
4
Drugs Scored
0.6x
rNPV / MCap
Top 33%
Small Cap(rank 218 of 658)
Percentile Rank
BioCryst Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $624M risk-adjusted pipeline value, led by BCX4161 in Hereditary Angioedema (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $940.6M x 4.1 = $3.9B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ORLADEYO | $617M | $532M | +16.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCX4161 Small moleculeCompletedNCT02218294 | Hereditary Angioedema | Phase 2 | COMPLETED | 169 | Sep 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every BCRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ORLADEYO | hereditary angioedema | Phase 1b/2 | 2026-06-12 | HAE attack rate: SOC 0.691 attacks/month (0-5.03), ORLADEYO 0.169 attacks/month (0-1.75); professional care attacks: SOC 22, ORLADEYO 3; attacks during week 37 48: 0Read More | BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Milne Jill C.Director | Grant/Award | 1,262 16,644 held | $8.91 | 05/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BCRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.4 % (-12.5 %) | 158.27 M | 15.83 M |
BCRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BCRX ranks across every disease it competes in
Competitive Position is a premium feature
See how BCRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBCRX News
BCRX▼ -1.4%today
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst Pharmaceuticals has established a Scientific Advisory Board to enhance its R&D efforts in rare diseases. The board includes seven experts who will guide the company in pipeline expansion and innovation strategies. This move reflects BioCryst's commitment to external collaboration and rigorous scientific evaluation as it seeks to develop new therapies.
Read more →BCRXBioCryst to Present at Upcoming Investor Conference
BioCryst Pharmaceuticals will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The presentation will be accessible via a live audio webcast. BioCryst is dedicated to developing treatments for hereditary angioedema and other rare diseases, and has already commercialized its first product.
Read more →BCRXBioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Pharmaceuticals has received marketing approval from Japan's MHLW for ORLADEYO (berotralstat) as a once-daily oral prophylactic therapy for pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. This approval is based on positive interim results from the APeX-P clinical trial, which demonstrated the drug's safety and efficacy. ORLADEYO is designed to ease the treatment burden traditionally associated with injections, offering a more convenient option for families managing HAE.
Read more →BCRXBioCryst Reports Second Quarter 2026 Financial Results
BioCryst reported strong financial results for the second quarter of 2026, with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million. The company achieved an operating profit of $98.5 million and a Non-GAAP operating profit of $113.2 million. Additionally, BioCryst maintained its revenue guidance for ORLADEYO and increased its total revenue guidance for the year.
Read more →BCRXBioCryst to Report Second Quarter 2026 Financial Results on August 5
BioCryst Pharmaceuticals has announced that it will report its second quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. BioCryst focuses on developing medicines for hereditary angioedema and other rare diseases.
Read more →BCRXBioCryst Appoints David W. Jenkins as Chief Scientific Officer
BioCryst Pharmaceuticals has appointed David W. Jenkins as Chief Scientific Officer, effective immediately. In this newly created role, he will lead a research team aimed at accelerating the development of therapies for rare diseases through external partnerships. Jenkins has over 20 years of experience in the biopharmaceutical industry, previously serving at Ipsen and other notable companies.
Read more →BCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals has announced the granting of stock options and restricted stock units to nine newly-hired employees as part of their inducement for joining the company. The total includes options for 33,950 shares and RSUs for 91,750 shares, with a vesting schedule over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4).
Read more →BCRXBioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
BioCryst Pharmaceuticals is shifting its focus towards external innovation by winding down its internal discovery programs and closing its Birmingham research facility. This strategic change aims to enhance the growth of its rare disease pipeline. Additionally, the company has completed enrollment in the Phase 3 ALPHA-ORBIT study for navenibart, marking it as the largest pivotal study for HAE to date. Furthermore, BioCryst has resolved a previously disclosed manufacturing delay for ORLADEYO.
Read more →BCRXBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Pharmaceuticals presented positive new clinical data for its HAE portfolio, particularly ORLADEYO and the investigational navenibart, at the EAACI Annual Meeting 2026. The data demonstrate significant reductions in HAE attack burden and healthcare utilization among diverse patient populations. The results, particularly from the ALPHA-STAR study, support the potential of navenibart as a long-acting treatment option. No significant safety issues were identified, reinforcing the strength of BioCryst's treatment offerings in hereditary angioedema.
Read more →BCRX▲ +7.7%on this news
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
BioCryst Pharmaceuticals will present seven abstracts related to its hereditary angioedema (HAE) portfolio at the EAACI Annual Meeting in Istanbul from June 12-15, 2026. The presentations will include new clinical trial data for ORLADEYO (berotralstat) and navenibart, highlighting their efficacy in reducing HAE attacks. ORLADEYO is the first oral prophylactic therapy for HAE, while navenibart is under investigation for its long-acting potential.
Read more →BCRX▲ +9.1%on this news
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
BioCryst Pharmaceuticals will present new real-world evidence at the ISPOR 2026 conference, focusing on the healthcare burden of hereditary angioedema in pediatric patients. The studies reveal significant healthcare resource utilization and the impact on caregivers' quality of life. The findings aim to highlight the unmet needs and the necessity for improved disease management.
Read more →BCRXBioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. reported strong financial results for Q1 2026, with ORLADEYO net revenue reaching $148.3 million. The company announced a licensing agreement for navenibart in Europe, providing $70 million upfront with potential milestone payments. BioCryst is making significant progress in pipeline programs, notably on track for regulatory filing for navenibart by late 2027. However, the company recorded a substantial GAAP operating loss primarily due to a special charge related to its acquisition activities.
Read more →BCRXBioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst Pharmaceuticals has entered into a licensing agreement with Neopharmed Gentili, granting exclusive rights to commercialize navenibart for hereditary angioedema in Europe. BioCryst will receive an upfront payment of $70 million and could earn up to $275 million in future milestone payments, along with tiered royalties on sales. The Phase 3 program for navenibart is expected to support a US regulatory filing by the end of 2027.
Read more →BCRXBioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals has announced its participation in two upcoming investor conferences. The first will be at the Bank of America Health Care Conference on May 12, 2026, followed by the Jefferies Global Healthcare Conference on June 3, 2026. The company aims to present its advancements in treatments for hereditary angioedema and other rare diseases.
Read more →BCRXBioCryst to Report First Quarter 2026 Financial Results on May 6
BioCryst Pharmaceuticals, Inc. has announced that it will report its first quarter 2026 financial results on May 6, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. This event highlights BioCryst's ongoing commitment to transparency and communication with stakeholders.
Read more →BCRXBioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as the new Chief Research and Development Officer. Dr. Menon, who previously held a similar role at Alnylam Pharmaceuticals, is expected to lead the company's efforts in advancing its rare disease therapies, particularly the navenibart program. His expertise in managing complex clinical programs and achieving regulatory approvals is anticipated to strengthen BioCryst's strategic direction and R&D capabilities as the company seeks to capitalize on its recent commercial successes. This leadership transition comes at a pivotal time for BioCryst, aiming to enhance its pipeline and overall growth.
Read more →About BioCryst Pharmaceuticals, Inc.
Headquarters4505 EMPEROR BOULEVARD, DURHAM, NC, 27703
Founded1986
BIOPHARMAWATCH ELITE PLUS
Trade the next BCRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime